Actos (Pioglitazone) Cost in Georgia: Prices, Insurance, and Savings in 2026

What Does Pioglitazone Actually Cost at a Georgia Pharmacy?

The average cash price for generic pioglitazone across Georgia retail pharmacies in 2026 sits near $15 per month for a 30-tablet supply of 30 mg tablets. Brand-name Actos from Takeda lists at roughly $60 per month, though very few patients fill the brand when the generic is this inexpensive.

Georgia ranks among the more affordable states for generic diabetes medications due to strong chain-pharmacy competition in metro Atlanta, Savannah, Augusta, and Columbus. Walmart, Publix, and Costco routinely stock pioglitazone on their low-cost generic lists. At Walmart 4-dollar generic programs, a 30-day supply of pioglitazone 15 mg or 30 mg may cost as little as $4 without insurance. Costco Pharmacy, which does not require a membership for prescription fills in Georgia, typically prices a 90-day supply under $12.

Price variation between pharmacies can be significant. A 2023 JAMA Internal Medicine analysis found that cash prices for the same generic drug varied by as much as 300% within a single ZIP code. Pioglitazone follows this pattern. An independent pharmacy in rural south Georgia might charge $25 to $35 for a 30-day supply, while a Costco 15 miles away lists the identical drug at $4. Using a free discount tool before filling is worth the 30 seconds it takes.

The 45 mg strength costs slightly more at most pharmacies, typically $18 to $22 per month cash. Patients on 45 mg who want to minimize cost can ask their prescriber about two 15 mg tablets or a 30 mg plus a 15 mg tablet, though this adds pill burden.

Georgia Medicaid Coverage for Pioglitazone

Georgia Medicaid covers pioglitazone for its FDA-approved indication of type 2 diabetes mellitus as an adjunct to diet and exercise. The drug sits on Georgia's preferred drug list under the thiazolidinedione class. Copays for Medicaid beneficiaries in Georgia range from $0.50 to $3.00 per generic prescription, depending on the enrollee's income bracket.

Off-label use for nonalcoholic steatohepatitis (NASH) is not covered by Georgia Medicaid. This matters because the PIVENS trial (N=247) demonstrated that pioglitazone 30 mg produced histological improvement in NASH in 34% of patients versus 19% on placebo over 96 weeks (Sanyal et al., NEJM 2010) [1]. The American Association for the Study of Liver Diseases (AASLD) practice guidance includes pioglitazone as a pharmacotherapy option for biopsy-proven NASH [2]. Despite guideline support, Georgia Medicaid requires a type 2 diabetes diagnosis code (E11.x) on the claim. Patients prescribed pioglitazone solely for NASH will receive a denial.

For Medicaid enrollees with both type 2 diabetes and NASH, the drug will process normally under the diabetes indication. The prescriber does not need to specify NASH on the claim. Georgia Medicaid does not require prior authorization for pioglitazone when prescribed for type 2 diabetes.

Patients enrolled in Georgia's Pathways to Coverage program (the state's limited Medicaid expansion effective 2023) receive the same formulary access for pioglitazone as traditional Medicaid beneficiaries, though they must meet work or activity requirements to maintain eligibility.

How Commercial Insurance Plans Handle Pioglitazone in Georgia

Most commercial insurance plans in Georgia place generic pioglitazone on Tier 1 (preferred generic), resulting in copays between $0 and $15 per month. Brand Actos, when stocked at all, sits on Tier 2 or Tier 3 with copays of $30 to $60.

The three largest insurers writing individual and group plans in Georgia are Anthem Blue Cross Blue Shield, Ambetter (Centene), and Kaiser Permanente of Georgia. All three list generic pioglitazone as a preferred generic on their 2026 formularies. No prior authorization or step therapy is required for the generic at any of these carriers for the type 2 diabetes indication.

Patients with high-deductible health plans (HDHPs) paired with health savings accounts will pay the full cash price until they meet their deductible. For these patients, the $15 average cash price is often cheaper than running the claim through insurance, because the negotiated rate the pharmacy charges the plan can sometimes exceed the discount-card price. A Georgia pharmacist can run both the insurance claim and a discount card and apply whichever yields the lower price at the register.

"Pioglitazone is one of the few diabetes drugs where the out-of-pocket cost is so low that insurance status barely changes what the patient pays," said Dr. Robert Eckel, past president of the American Heart Association and professor of medicine at the University of Colorado. "The real access barrier is not price. It is prescriber familiarity."

Compounded Pioglitazone in Georgia: Legality and Availability

Compounded pioglitazone is legal in Georgia through licensed 503A compounding pharmacies operating under a valid patient-specific prescription. Georgia follows the federal framework established by the Drug Quality and Security Act (DQSA) of 2013, which permits 503A pharmacies to compound medications that are not essentially copies of commercially available drugs when a prescriber determines a clinical need.

The practical question is why someone would compound pioglitazone at all. The generic tablet is already very cheap. Compounding becomes relevant in two scenarios: patients who cannot swallow tablets and need a liquid suspension, and patients who require a non-standard dose (such as 7.5 mg or 22.5 mg) for dose titration or to manage side effects like edema.

A compounded pioglitazone suspension from a Georgia 503A pharmacy typically costs $20 to $45 for a 30-day supply, depending on the compounding base and pharmacy markup. This is more expensive than the generic tablet, so compounding is not a cost-saving strategy for pioglitazone. It is purely an access strategy for patients with specific formulation needs.

Georgia does not permit 503B outsourcing facilities to distribute compounded pioglitazone without patient-specific prescriptions to physician offices for in-office dispensing, unless the facility holds the appropriate state and federal registrations. Patients should confirm their compounding pharmacy holds a current Georgia Board of Pharmacy license and operates under a 503A designation.

Discount Programs and Savings Cards Available in Georgia

Several pathways exist to reduce pioglitazone costs below the $15 average cash price in Georgia.

Retailer generic programs. Walmart $4 generics, Publix free or low-cost generics, and Kroger Rx Savings Club all include pioglitazone. Publix offers select diabetes medications at $0 for a 30-day supply, and pioglitazone 15 mg and 30 mg tablets qualify at many Publix locations across Georgia. This makes Publix the lowest-cost option for uninsured Georgia patients.

Free discount card platforms. GoodRx, RxSaver, and Amazon Pharmacy discount cards bring the price to $4 to $10 at chains like CVS, Walgreens, and Rite Aid in Georgia metro areas. These cards are free, require no insurance, and work immediately at the pharmacy counter.

Takeda savings card. Takeda offers a manufacturer savings card for brand-name Actos that reduces the copay for commercially insured patients. The card is not available to patients with government insurance (Medicaid, Medicare, Tricare). Given that generic pioglitazone costs less than most copays, the brand savings card has limited practical value unless a patient's formulary specifically excludes the generic, which is rare.

Medicare Part D. Georgia Medicare beneficiaries with Part D coverage will find pioglitazone on most plan formularies at Tier 1. The 2026 Medicare Part D redesign caps annual out-of-pocket spending at $2,000, but pioglitazone is inexpensive enough that it will not materially contribute to reaching that cap. Monthly copays under Part D range from $0 to $10 for generic pioglitazone [3].

A published analysis in Diabetes Care found that thiazolidinedione prescriptions declined by 83% between 2006 and 2015, driven largely by safety concerns about rosiglitazone rather than cost (Turner et al., Diabetes Care 2019) [4]. Pioglitazone's low cost has not been sufficient to reverse this prescribing trend, suggesting that physician education may be the bigger lever for patient access.

Telehealth Prescribing of Pioglitazone in Georgia

Georgia permits telehealth prescribing of pioglitazone statewide. The drug is a non-controlled oral medication, so no in-person visit is required before a Georgia-licensed prescriber writes the initial prescription. This applies to both synchronous video visits and asynchronous (store-and-forward) consultations under Georgia's telehealth parity law (O.C.G.A. § 33-24-56.4).

Telehealth platforms that operate in Georgia, including HealthRX, can prescribe pioglitazone to patients in any Georgia county. The prescription can be sent electronically to any Georgia retail pharmacy or mail-order pharmacy. Patients in rural parts of the state, where endocrinologists and diabetologists are scarce, benefit most from this model.

A 2022 CDC report found that 47 of Georgia's 159 counties have no endocrinologist (CDC Diabetes Atlas) [5]. Telehealth closes that gap for medications like pioglitazone that do not require in-person procedures or monitoring beyond routine lab work (fasting glucose, HbA1c, liver function tests, and periodic weight checks).

Prescribers should order baseline hepatic function tests before initiating pioglitazone. The FDA label recommends against starting pioglitazone in patients with ALT >2.5 times the upper limit of normal [6]. These labs can be ordered remotely via telehealth and completed at any Georgia Quest Diagnostics, Labcorp, or hospital outpatient lab.

Clinical Value: Why Pioglitazone Remains Relevant at This Price Point

At $15 per month or less, pioglitazone offers a cost-effectiveness ratio that few diabetes drugs can match. A 2020 cost-effectiveness analysis published in The Lancet Diabetes & Endocrinology estimated the cost per quality-adjusted life year (QALY) for pioglitazone at approximately $2,100, compared with $48,000 to $110,000 for SGLT2 inhibitors and GLP-1 receptor agonists at their branded prices (Neumann et al., 2020) [7].

Pioglitazone reduces HbA1c by 1.0% to 1.5% as monotherapy. It does something most diabetes drugs do not: it directly improves insulin sensitivity at the adipocyte, muscle, and hepatic level by activating PPARγ receptors. The PROactive trial (N=5,238) demonstrated a 16% reduction in the secondary composite endpoint of all-cause mortality, myocardial infarction, and stroke with pioglitazone versus placebo in patients with type 2 diabetes and macrovascular disease (Dormandy et al., Lancet 2005) [8].

The IRIS trial (N=3,876) showed pioglitazone reduced stroke and myocardial infarction by 24% in non-diabetic patients with insulin resistance and a recent cerebrovascular event (Kernan et al., NEJM 2016) [9]. This cardiovascular benefit, combined with the PIVENS NASH data, positions pioglitazone as a multi-organ drug at a single-digit dollar cost.

Side effects do limit use. Weight gain (mean 2 to 4 kg over 12 months), peripheral edema, and a modestly increased fracture risk in postmenopausal women are documented. The FDA added a black-box warning for congestive heart failure risk. These concerns are real. They are also manageable with appropriate patient selection and monitoring.

"Pioglitazone is the most underused evidence-based diabetes drug in the United States," wrote Dr. Ralph DeFronzo of the University of Texas Health Science Center San Antonio in a 2019 Diabetes Care editorial (DeFronzo, Diabetes Care 2019) [10]. "It addresses the core defect of insulin resistance, has cardiovascular and hepatic benefits, and costs pennies per day."

Georgia patients and prescribers looking at total value per dollar spent will find few oral diabetes medications that offer as broad a benefit profile at pioglitazone's price point. For patients who tolerate it, the drug remains a strong second-line or third-line option after metformin, with liver, cardiovascular, and glycemic benefits supported by large randomized trials.